Table 4 Cox proportional hazards model analysis for the composite primary endpoints.

From: Novel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study

 

Univariate HR

95%CI

P value

Multivariate HR

95%CI

P value

E-HD

0.687

0.454-1.039

0.076

0.593

0.384–0.916

0.019

HD vintage

1.000

0.997–1.002

0.824

   

Age

1.036

1.017–1.055

0.000

1.014

0.993–1.036

0.183

Gender (female)

0.698

0.454–1.074

0.102

   

History of CVD

3.085

2.040–4.665

0.000

3.037

1.977–4.665

0.000

non DM

0.865

0.569–1.314

0.497

   

BMI

0.987

0.933–1.044

0.644

   

Pre SBP

0.999

0.990–1.007

0.783

   

Albumin

0.195

0.101–0.377

0.000

0.328

0.160–0.674

0.002

CRP

1.266

1.017–1.576

0.035

1.323

1.005–1.740

0.046

Hg

0.893

0.741–1.075

0.230

   
  1. E-HD, electrolyzed water haemodialysis; HD, haemodialysis; CVD, cardio-cerebral vascular disease; DM, diabetes mellituss; BMI, body mass index; Pre SBP, pre-dialysis systolic blood pressure; CRP, C-reactive protein; Hg, hemoglobin.
Back to article page